John Chandy C, Moormann Ann M, Pregibon Daniel C, Sumba Peter Odada, McHugh Marilyn M, Narum David L, Lanar David E, Schluchter Mark D, Kazura James W
Center for Global Health and Diseases, Rainbow Center for International Child Health, Division of Pediatric Infectious Diseases, Case Western Reserve University, Cleveland, Ohio, USA.
Am J Trop Med Hyg. 2005 Jul;73(1):222-8.
High levels of antibodies to multiple antigens may be more strongly associated with protection from infection than antibodies to a single antigen. Antibody-associated protection against Plasmodium falciparum infection was assessed in a cohort of 68 adults living in an area of holoendemic malaria in Kenya. Antibodies to the pre-erythrocytic antigens circumsporozoite protein (CSP), liver-stage antigen-1 (LSA-1), thrombospondin-related adhesive protein (TRAP), and blood-stage antigens apical membrane antigen-1 (AMA-1), erythrocyte binding antigen-175 (EBA-175), and merozoite surface protein 1 (MSP-1) were tested. Peptides were used for CSP (NANP repeat) and LSA-1 (central repeat), and recombinant antigens were used for TRAP (aa D(48)-K(394)), AMA-1 (ectodomain, non-glycosylated), EBA-175 (non-glycosylated), and MSP-1 (MSP-1(19)). Weekly microscopy testing for P. falciparum infection was performed over a 12-week period after drug-mediated clearance of P. falciparum parasitemia. Individuals with high levels of IgG antibodies (> 2 arbitrary units) to CSP, LSA-1, and TRAP had a 57% decrease in the risk of infection (95% confidence interval = 20-77%, P = 0.016). This decreased risk remained significant after adjustment for age, prior parasitemia, bed net use, sickle cell trait, and village of residence. In contrast, protection against infection did not correlate with high levels of IgG antibodies to blood-stage antigens or IgM antibodies to pre-erythrocytic or blood-stage antigens. High levels of IgG antibodies to CSP, LSA-1, and TRAP may be useful immune correlates of protection against P. falciparum infection in malaria-endemic populations.
与单一抗原的抗体相比,针对多种抗原的高水平抗体可能与预防感染的关联更强。在肯尼亚疟疾高度流行地区居住的68名成年人队列中,评估了抗体介导的针对恶性疟原虫感染的保护作用。检测了针对疟原虫感染前期抗原环子孢子蛋白(CSP)、肝期抗原-1(LSA-1)、血小板反应蛋白相关黏附蛋白(TRAP)以及感染期抗原顶端膜抗原-1(AMA-1)、红细胞结合抗原-175(EBA-175)和裂殖子表面蛋白1(MSP-1)的抗体。CSP(NANP重复序列)和LSA-1(中央重复序列)使用肽段,TRAP(氨基酸D(48)-K(394))、AMA-1(胞外结构域,非糖基化)、EBA-175(非糖基化)和MSP-1(MSP-1(19))使用重组抗原。在药物清除恶性疟原虫血症后的12周内,每周进行恶性疟原虫感染的显微镜检测。对CSP、LSA-1和TRAP具有高水平IgG抗体(>2个任意单位)的个体感染风险降低了57%(95%置信区间=20-77%,P=0.016)。在调整年龄、既往疟原虫血症、蚊帐使用、镰状细胞性状和居住村庄后,这种降低的风险仍然显著。相比之下,针对感染的保护作用与针对感染期抗原的高水平IgG抗体或针对感染前期或感染期抗原的IgM抗体无关。针对CSP、LSA-1和TRAP的高水平IgG抗体可能是疟疾流行地区预防恶性疟原虫感染的有用免疫相关指标。